Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) announced late-breaking topline data from a phase 2 study conducted in China testing varlitinib and capecitabine in second line BTC patients. The data was presented during an oral session by Dr Weijia Fang, Associated Chief Physician, MD, Department of Medical Oncology, Zhejiang University, at the 2019 Chinese Society of Clinical Oncology (CSCO) meeting in Xiamen, China.
For more information, please refer to the English or Chinese press release.
The abstract is available to view here: JADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC)